Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study’”

To the Editor: We thank Dr Kridin for his interest in our recent publications.1,2 The limitation that we may have not been able detect the association between newer diabetes drugs and bullous pemphigoid (BP) was already acknowledged in our previous article.1 The unpublished finding of Dr Kridin's group that the use of linagliptin is associated with BP is not surprising and further confirms the significance of the use of dipeptidyl peptidase 4 inhibitors (DPP4is) (or gliptins) as a risk factor for BP.

https://ift.tt/2OyXrCj